iiinova — where your digital self keeps evolving

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 06/01/2025

A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed? Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻 doi.org/10.1016/j.es...

doi.org

Redirecting

000 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 30/12/2024

Now that it’s official, I can finally celebrate: I’ve been awarded a Juan Rodés contract starting in 2025, ranking 1st in 🇪🇸! Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸!

110 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor. 2nd line PFS >11 months with fulvestrant. Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores. Hoping this one moves forward! #SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

22211 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

Elisa Agostinetto @elisaagostinetto.bsky.social · 11/12/2024

At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT ⬆️TTF and PFS w/palbo+ET Reassuring data supporting 1st line CDK4/6i+ET as SoC @oncoalert.bsky.social

184 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 11/12/2024

My first takeaway from #SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2 👇🏻

120 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

Elad Sharon, MD, MPH @eladsharonmd.bsky.social · 26/11/2024

One of the most important multi-cancer analyses on #ImmuneRelatedAdverseEvent grading and clinical outcome is out this week from @JNCI : buff.ly/499OIBj

094 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 28/11/2024

Finally out in @ESMO_Open the main findings of my #ESMO #Fellowship research project focused on the identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵

192 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

Paolo Tarantino, MD @ptarantinomd.bsky.social · 17/11/2024

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!

39534 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 22/11/2024

Ready for the #envisionsummit2024 from #SOLTI with great speakers diving deep into the future of prognostic/predictive biomarkers in #breastcancer and new treatment strategies

151 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/11/2024

Aneuploid cells were primarily associated w/luminal epithelial lineages and localized in ductal & lobular structures without apparent histopathological abnormalities. Suggests clonal expansions of aneuploid cells are a normal feature of healthy breast tissues. #BreastCancer buff.ly/3V1rbwT

083 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/11/2024

ACOG recommends starting mammography at age 40 for those at average breast cancer risk, due to a 2% annual increase in cases among women aged 40-49 from 2015 to 2019. This update aligns with other major health organizations, advising continued screening every 1 to 2 years. buff.ly/3UVMgJ0

063 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 20/11/2024

Useful updated treatment algorithms for HR+ #breastcancer from @ilanaschlam.bsky.social We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)

040 0

Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺

The OncoAlert Network 🚨 @oncoalert.bsky.social · 19/11/2024

Preferences for speed of access versus certainty of the survival benefit of new cancer drugs Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages. buff.ly/3ZbZyU2

084 0

Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺 @schettinif87.bsky.social · 19/11/2024

Ok let’s see how this app works. First post (taken from De Ashley Rubin, who I think is not on 🦋) very nice and helpful for researchers “lost in descriptionland”. I’ll use screenshots of her X thread.

030 0